Lead Exposure
Conditions
Keywords
Blood/Urine/Hair lead, Lead uptake & Lead bioavailability
Brief summary
This is a prospective, randomized, placebo-controlled, double blind, parallel-arm study in a two-staged approach that will assess the effect of two different doses of G-PUR® on enteral lead absorption in healthy adults using a stable lead isotopic tracer (204Pb).
Interventions
DEVICEG-PUR® 2x 2.0 g oral suspension
Cohort 1: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before and immediately after 204Pb intake
DEVICEG-PUR® 1x 2.0 g oral suspension
Cohort 2: 2 g G-PUR® powder mixed with 100 ml water in an opaque drinking bottle will be orally administered before 204Pb intake and 100 ml water (placebo) in an opaque drinking bottle immediately after 204Pb intake
DEVICEPlacebo oral suspension
Cohort 3: 100 ml of water in an opaque drinking bottle will be orally administered immediately before and after 204Pb intake
Sponsors
Glock Health, Science and Research GmbH
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy male and female subjects 2. Age 18-45 years 3. BMI 19-27 for males and BMI 17-25 for female 4. Blood lead (PbB) concentration \< 40 μg/l 5. Serum ferritin concentration within the sex-specific normal range, i.e. ≥ 15 - 150 ng/ml for women and 30 - 400 ng/ml for men 6. Presence of scalp hair with a minimum length of 5 mm and willingness to remove 5 single hairs with hair roots at end of study visit 7. Subject is in good clinical and mental health as established by medical history and physical examination 8. Stable eating habits, within one month before the start of the study 9. Subject agrees to be compliant for study related diet schedule 10. Women of childbearing potential agree to use adequate birth control methods during the study (for all females, negative pregnancy test at screening and at Visit 3 before dosing of IMD is required. Females of childbearing potential must use adequate contraception during the entire study period. Acceptable methods of contraception include: oral contraceptives, intrauterine device, female or male condoms with spermicide, diaphragm with spermicide, contraceptive medication patch, contraceptive medication implant, contraceptive medication injection, abstinence, or surgical sterilization more than 3 months before randomization. 11. Written informed consent
Exclusion criteria
1. Pregnancy and breastfeeding 2. Lack of willingness or capacity to co-operate appropriately 3. Regular use of medications or iron supplements in the previous 2 months except intake of contraceptives 4. Planning to shave head during study 5. History of malignancies within the past two years or on current anticancer treatment 6. History of gastrointestinal pathology such as gastritis, gastric ulcers, irritable bowel disease, inflammatory bowel disease, chronic constipation 7. History of diarrhoea within the past 14 days of screening 8. History of gastrointestinal surgery with exception of appendectomy 9. History of chronic autoimmune disease requiring treatment within the past two months of screening 10. Known diabetes mellitus I or II or Hba1c \>6.5% 11. Known symptomatic food allergies 12. Any clinically relevant laboratory abnormalities in screening test 13. Alcohol, cigarette or drug abuse 14. Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study 15. Presence of any condition that impacts compliance with the study procedures 16. Use of any regular medication (prescription or over the counter) for prevention or treatment of any medical condition 17. Use of any investigational or non-registered product (drug or device) within 30 days preceding the first study product administration, or planned use during the study period 18. Employee at the study site, spouse/partner or relative of any study staff (e.g. investigator, sub-investigators, or study nurse) or relationship to the sponsor 19. IMD should not be applied to patients that suffer from aluminium and/or silicon hypersensitivity or in case of renal failure that requires dialysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 204PbB Cmax normalized for total PbB | 216 hours | Cmax of 204PbB normalized for total natural PbB levels after intake of 204Pb-enriched water |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of (S)ADE | 216 hours | Incidence of (serious) adverse device effects |
| Plasma PK parameters - AUC0-t of 204PbB | 216 hours | The observed area under the blood concentration versus time curve between time 0 and the time point of the last quantifiable concentration, calculated using the trapezoidal rule method |
| Plasma PK parameters - tmax of 204PbB | 216 hours | Time to reach the peak concentration: The sampling time at which Cmax was observed |
| 204Pb concentrations in 24-hour urine | 24 hours | Measurement of 204Pb isotope tracer concentrations in 24-hour urine after intake of 204Pb enriched water |
| 204Pb in single hairs | 9 days | Lead isotope tracer (204Pb) distribution and ratio in single hairs |
Countries
Austria
Outcome results
None listed